Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass

Hayashida, Nobuhiko; Tomoeda, Hiroshi; Oda, Tatsuya; Tayama, Eiki; Chihara, Shingo; Kawara, Takemi; Aoyagi, Shigeaki

doi:10.1016/s0003-4975(99)00716-x

Cited by 63 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We suggest that this absence of proof may be due to inadequate dosing, a wrong model, and limited use of PDE3 inhibitors. However, clinical data suggest that PDE3 inhibition therapy given via infusion in heart failure, bypass operations, and enterovirus 71 infection did show antiinflammatory effects (37)(38)(39). During the last decade, a growing number of studies suggest that PDE3 inhibition might be involved in immunosuppression (40)(41)(42)(43)(44)(45)(46)(47)(48), although there is no definitive proof.…”

Section: Introductionmentioning

confidence: 99%

A pathophysiological role of PDE3 in allergic airway inflammation

et al. 2018

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A pathophysiological role of PDE3 in allergic airway inflammation

et al. 2018

View full text Add to dashboard Cite

“…If cytokine production can be reduced during and after CPB, post-surgical problems such as cardiac dysfunction and respiratory distress syndrome can potentially be prevented. Pharmacological agents to minimize the cytokine responses,the use of heparin-coated lines and hemofiltration after CPB are being investigated [14]. Mannacio et al in 2008 reported postoperative assessments of troponin I, myoglobin, creatine kinase-MB and hs-CRP;however, in our study, both proinflammatory cytokines (IL-6 and IL-18) and antiinflammatory cytokine (IL-10) were measured [15].…”

Section: Discussionmentioning

confidence: 63%

Rosuvastatin Lowers Systemic Inflammatory Response in Coronary Artery Bypass Graft Accompanied by Cardiopulmonary Bypass Surgery: A Randomized Controlled Study

Özgüler¹,

Burma²,

Uysal³

et al. 2015

CIM

View full text Add to dashboard Cite

Purpose: Cardiopulmonary bypass (CPB) is commonly associated with a systemic inflammatory response that may lead to severe complications. Classic signs of systemic inflammatory response syndrome are complement activation and changes in cytokine and acute phase reactant levels. The effects of rosuvastatin after CPB on interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-18 (IL-18) and High Sensitivity C-Reactive Protein (hs-CRP) levels were investigated.Methods: Thirty-seven male and thirteen female patients (total=50) aged 42 to 78 years, who had coronary bypass surgery due to coronary artery disease were randomly divided into two groups. The 25 patients in the control group were administered placebos. The 25 in the treatment group were administered 20 mg rosuvastatin tablets daily between preoperative day 7 and postoperative day 28. Blood samples were taken at six time points; before induction of anesthesia (T1), during CPB (T2), five minutes after removal of cross clamp (T3), after protamine infusion (T4), postoperative day three (T5) and postoperative day 28 (T6). Data points were expressed as mean ± standard deviation (SD).Results: Rosuvastatin lowered IL-6 levels at T4, T5 and T6 time points (T4, T5, T6 p < 0.05), and elevated IL-10 levels at T3 and T4 (T3, T4 p < 0.05). IL-18 levels were also elevated at multiple time points. Rosuvastatin also lowered hs-CRP levels and cholesterol levels at T6 (p < 0.05). Conclusion:Administering 20 mg/day of rosuvastatin between preoperative day 7 and postoperative day 28 may result in fewer complications in certain (especially intraoperative) cases of systemic inflammatory response caused by the CPB technique used in coronary bypass surgery.

show abstract

“…Several studies have indicated that intravenous administration of milrinone inhibits cardiac surgery-related inflammation in experimental rodents and in patients [8,10,17]. Treatment with milrinone inhibits lipopolysaccharide-induced TNF-α production by cultured rat cardiac tissues in vitro [17].…”

Section: Discussionmentioning

confidence: 99%

“…Phosphodiesterase (PDE3) inhibitors can increase intracellular cAMP by inhibition of phosphodiesterase enzyme [6,7]. Various studies have demonstrated that PDE3 inhibitor could mitigate lipopolysaccharide-induced endothelial injury and inflammation, and promote postischemic recovery in tissues and organs [8,9,10,11]. …”

Section: Introductionmentioning

confidence: 99%

Preoperative Inhalation of Milrinone Attenuates Inflammation in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Gong

Lin

et al. 2011

Med Princ Pract

View full text Add to dashboard Cite

Objectives: The purpose of this study was to evaluate the effect of preoperative inhalation of milrinone on cardiopulmonary bypass (CPB)-related inflammation. Subjects and Methods: A total of 30 patients undergoing cardiac surgery were recruited and randomized for preoperative inhalation of milrinone (Mil group) or normal saline (NS group), respectively. Each group had 15 patients. Their hemodynamic parameters were measured and blood samples were obtained longitudinally. The levels of serum interleukin (IL-6), tumor necrosis factor-α (TNF-α), and matrix metalloproteinase (MMP)-9 were determined by ELISA. Results: The levels of serum IL-6, TNF-α, and MMP-9 significantly increased at the end of cardiac surgery and remained high for 24 h in both groups of patients. However, the levels of proinflammatory cytokines at the end of cardiac surgery in the Mil group of patients were significantly lower than those of the NS group of patients. Conclusions: Our data indicated that preoperative inhalation of milrinone significantly mitigated CPB-related inflammation.

show abstract

Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass

Cited by 63 publications

References 21 publications

A pathophysiological role of PDE3 in allergic airway inflammation

A pathophysiological role of PDE3 in allergic airway inflammation

Rosuvastatin Lowers Systemic Inflammatory Response in Coronary Artery Bypass Graft Accompanied by Cardiopulmonary Bypass Surgery: A Randomized Controlled Study

Preoperative Inhalation of Milrinone Attenuates Inflammation in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Contact Info

Product

Resources

About